The pre-mRNA exon skipping approach using RNA or DNA antisense oligonucleotides (AONs) is grounded on the fact that most DMD patients can theoretically produce dystrophin similar to that produced in BMD patients if the reading frame is corrected. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.